Commentary: The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy DOI Creative Commons
Pengfei Zhang, Liping Jia, Linhan Wang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 27, 2025

The review by Yongmei Wang et al., "The ubiquitin-proteasome system in the tumor immune microenvironment: a key force combination therapy," provides comprehensive analysis of UPS's role TIME, highlighting its potential as therapeutic target immunotherapy [1]. Despite this, could benefit from more detailed discussion on impact transcription factor FOXP3, regulation cell function E3 ubiquitin-protein ligases, and emerging Proteolysis Targeting Chimeras (PROTACs) modulating ligase activity. FOXP3 stability [2].The activity expression are regulated various such CBLB STUB1. These mechanisms should be elaborated upon to provide understanding how UPS influences Treg biology [7].Identifying ligases their cancers like breast cancer can new targets for patients, especially those with advanced, recurrent, metastatic disease [8].In terms drug development, there has been significant progress targeting therapy. Proteasome inhibitors, bortezomib, have approved treatment multiple myeloma mantle lymphoma [9]. Additionally, development deubiquitinating enzyme (DUB) inhibitors is an area research, several compounds entering preclinical clinical trials [10]. For instance, USP7 inhibitor P5091 shown promise promoting ubiquitination degradation MDM2, thereby activating p53 pathway [11].The also thorough summary current research targets. SPOP FBXO22, ubiquitinate degrade PD -L1, suggesting that inhibition enhance anti-tumor responses [11]. Furthermore, neddylation regulating CRL complexes highlighted, disrupt TAM recruitment evasion .Proteolysis i s promising strategy [12], one end protein interest (POI) other binding ubiquitin ligase. By

Language: Английский

The Role of the Ubiquitin System in Eye Diseases DOI Creative Commons
Sandra Carolina Durán-Cristiano, Laura de Diego‐Garcia, Alba Martín‐Gil

et al.

Life, Journal Year: 2025, Volume and Issue: 15(3), P. 504 - 504

Published: March 20, 2025

The ubiquitin–proteasome system (UPS) is a fundamental process that regulates various biological functions, including immune response, cell cycle, oxidative stress, migration, and cellular proliferation. This responsible for the degradation of proteins, while proteasomes play significant role in mechanisms involved health human diseases. participation UPS response particularly relevant, leading to involvement immunoproteasomes. specialized proteasome processing presentation antigenic peptides, making it crucial proper function. Moreover, impact considered essential understanding several diseases, such as neurodegenerative disorders, infections, vascular dysregulation may contribute pathogenesis these conditions, highlighting its importance potential therapeutic target. Interestingly, also related ocular structures, playing visual perception homeostasis. regulation processes suggests on both anterior posterior eye pathologies. review aims discuss general considerations provide information about By disease, researchers clinicians explore novel strategies targeting treatment conditions. In conclusion, player processes, with far-reaching implications segments eye. Further research this field lead development innovative therapies better complex underlying disorders.

Language: Английский

Citations

0
Commentary: The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy DOI Creative Commons
Pengfei Zhang, Liping Jia, Linhan Wang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 27, 2025

The review by Yongmei Wang et al., "The ubiquitin-proteasome system in the tumor immune microenvironment: a key force combination therapy," provides comprehensive analysis of UPS's role TIME, highlighting its potential as therapeutic target immunotherapy [1]. Despite this, could benefit from more detailed discussion on impact transcription factor FOXP3, regulation cell function E3 ubiquitin-protein ligases, and emerging Proteolysis Targeting Chimeras (PROTACs) modulating ligase activity. FOXP3 stability [2].The activity expression are regulated various such CBLB STUB1. These mechanisms should be elaborated upon to provide understanding how UPS influences Treg biology [7].Identifying ligases their cancers like breast cancer can new targets for patients, especially those with advanced, recurrent, metastatic disease [8].In terms drug development, there has been significant progress targeting therapy. Proteasome inhibitors, bortezomib, have approved treatment multiple myeloma mantle lymphoma [9]. Additionally, development deubiquitinating enzyme (DUB) inhibitors is an area research, several compounds entering preclinical clinical trials [10]. For instance, USP7 inhibitor P5091 shown promise promoting ubiquitination degradation MDM2, thereby activating p53 pathway [11].The also thorough summary current research targets. SPOP FBXO22, ubiquitinate degrade PD -L1, suggesting that inhibition enhance anti-tumor responses [11]. Furthermore, neddylation regulating CRL complexes highlighted, disrupt TAM recruitment evasion .Proteolysis i s promising strategy [12], one end protein interest (POI) other binding ubiquitin ligase. By

Language: Английский

Citations

0